Bone Biologics Corporation (BBLGW)
| Market Cap | 2.26M -22.3% |
| Revenue (ttm) | n/a |
| Net Income | -3.11M |
| EPS | -2.65 |
| Shares Out | 1.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 9.76 |
| Previous Close | 27.00 |
| Day's Range | 9.76 - 16.80 |
| 52-Week Range | 8.30 - 35.95 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 2, 2026 |
About BBLGW
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or b... [Read more]
News
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq compliance Key accomplishments include expanded rhNELL-1 shelf lif...
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
Milestone advances manufacturing readiness and supports long-term commercialization strategy Milestone advances manufacturing readiness and supports long-term commercialization strategy
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics Announces Closing of $5.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Why Is Bone Biologics Stock Surging On Friday?
Bone Biologics Corporation BBLG stock is trading higher on Friday, with a session volume of 17.22 million compared to the average volume of 38.795K as per data from Benzinga Pro.
Bone Biologics Announces Pricing of $5.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Files Patent Application for Bone Regeneration Technology
BURLINGTON, Mass.--(BUSINESS WIRE)---- $BBLG #Bonebiologics--Bone Biologics files U.S. patent application for bone regeneration technology.
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Announces 1-for-6 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the ...
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that...
Bone Biologics Announces Closing of $2.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Announces Pricing of $2.0 Million Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Reports Progress With NB1 Clinical Program
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1...
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Announces 1-for-8 Reverse Stock Split
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced r...
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agr...
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiative...
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Bone Biologics stock plummets more than 50% after stock offering prices at deep discount
Shares of Bone Biologics Corp. BBLG plummeted 51.9% toward a record low in premarket trading Thursday, after the developer of regenerative medicine for bones announced the pricing of its relatively la...
Bone Biologics Prices $5.0 Million Underwritten Public Offering
BURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (NASDAQ: BBLG) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced the p...